Pegbelfermin Improves Non-Alcoholic Fatty Livers in Mid-Stage Trial Pegbelfermin Improves Non-Alcoholic Fatty Livers in Mid-Stage Trial

Pegbelfermin reduced the hepatic-fat fraction in patients with non-alcoholic steatohepatitis (NASH) in a phase 2a trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news